Ultragenyx to Participate at Investor Conferences in March

Core Insights - Ultragenyx Pharmaceutical Inc. is focused on developing and commercializing novel therapies for serious rare and ultrarare genetic diseases [1] - The company will participate in three upcoming investor conferences, showcasing its commitment to engaging with the investment community [1][2][3][4] Conference Participation - At the 45th Annual Cowen Healthcare Conference in Boston, MA on March 3, 2025, Eric Crombez, M.D., Chief Medical Officer, will participate in a fireside chat and host one-on-one meetings [2] - At the Barclays 27th Annual Global Healthcare Conference in Miami, FL on March 11, 2025, Eric Crombez will again participate in a fireside chat and host one-on-one meetings [3] - At the Leerink Partners Global Biopharma Conference in Miami, FL on March 12, 2025, Eric Crombez will participate in a fireside chat and host one-on-one meetings, with a live and archived webcast available on the company's website [4] Company Overview - Ultragenyx is committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases, with a diverse portfolio of approved therapies and product candidates [5] - The management team has extensive experience in the development and commercialization of rare disease therapeutics, focusing on time- and cost-efficient drug development [6]